Company Description
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.
The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture.
This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing.
The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers.
The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen
| Country | Germany |
| Founded | 1863 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 96,931 |
| CEO | William N. Anderson |
Contact Details
Address: 48 Wall Street, C/o Security Pacific Nat'l Trust Co Ny New York, New York 10286 United States | |
| Phone | 2124951727 |
| Website | bayer.com |
Stock Details
| Ticker Symbol | BAYRY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000790075 |
| CUSIP Number | 072730302 |
| ISIN Number | US0727303028 |
| SIC Code | 8880 |
Key Executives
| Name | Position |
|---|---|
| William N. Anderson | Chairman of the Management Board and Chief Executive Officer |
| Wolfgang U. Nickl | Chief Financial Officer and Member of Management Board |
| Heiko W. J. Schipper | Member of Management Board and President of the Consumer Health Division |
| Stefan Oelrich | Head of the Pharmaceuticals Division and Member of the Board of Management |
| Rodrigo Santos | Member of Management Board and President of the Crop Science Division |
| Heike Prinz | Chief Talent Officer, Labor Director and Member of Management Board |
| Julio Triana | Member of Management Board and President of Consumer Health Division |
| Dr. Sebastian Guth Ph.D. | Chief Operating Officer |
| Dr. Jost Reinhard | Head of Investor Relations |
| Michael Preuss | Head of Communications, Government Relations and Corporate Brand |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 24, 2023 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Apr 23, 2018 | EFFECT | Notice of Effectiveness |
| Apr 13, 2018 | F-6 | Filing |
| Sep 26, 2017 | 424B3 | Prospectus |
| Sep 21, 2017 | 424B3 | Prospectus |